← FDA DRUG APPROVALS

FDA ANDA · ANDA072622

ACETYLCYSTEINE

Sponsor: ROXANE

APPLICATION
ANDA072622
TYPE
ANDA
ORIGINAL APPROVAL
1992-09-30
LATEST ACTION
2000-08-28
ROUTE
INHALATION, ORAL
DOSAGE FORM
SOLUTION
MARKETING STATUS
Discontinued

Products

ACETYLCYSTEINEDiscontinued
ACETYLCYSTEINE 20% · SOLUTION · INHALATION, ORAL

Approval history

2000-08-28Manufacturing (CMC) · Supplement 5AP
1999-05-25Labeling · Supplement 4AP
1998-04-13Manufacturing (CMC) · Supplement 3AP
1998-04-13Manufacturing (CMC) · Supplement 2AP
1996-08-28Manufacturing (CMC) · Supplement 1AP
1992-09-30OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →